# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate...
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces...
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate o...
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday.